Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Resectable Pancreatic Ductal Adenocarcinoma (PDAC)”

21 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 21 results

Not applicableUnknownNCT05489458
What this trial is testing

Predictive Factors for Resection and Survival in Type A Borderline Resectable Pancreatic Ductal Adenocarcinoma Patients After Neoadjuvant Therapy

Who this might be right for
Carcinoma, Pancreatic Ductal
BUSQUETS, JULI 100
Testing effectiveness (Phase 2)Ended earlyNCT01096732
What this trial is testing

Hedgehog Inhibition for Pancreatic Ductal Adenocarcinoma (PDAC) in the Preoperative Setting (HIPPoS)

Who this might be right for
Pancreatic Ductal Adenocarcinoma
Lisa Bax 3
Early research (Phase 1)Not Yet RecruitingNCT06913218
What this trial is testing

MRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC

Who this might be right for
Pancreas CancerPancreas Cancer, Duct Cell Adenocarcinoma
Akeso 60
Large-scale testing (Phase 3)Looking for participantsNCT07252232
What this trial is testing

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Who this might be right for
Pancreatic CancerPDACPDAC - Pancreatic Ductal Adenocarcinoma+2 more
Revolution Medicines, Inc. 500
Testing effectiveness (Phase 2)Looking for participantsNCT06782932
What this trial is testing

Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer

Who this might be right for
Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 38
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06361030
What this trial is testing

Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer

Who this might be right for
Pancreatic CancerPancreatic Cancer Non-resectablePancreatic Ductal Adenocarcinoma, PDAC
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 40
Testing effectiveness (Phase 2)Looking for participantsNCT06060405
What this trial is testing

Durvalumab and Oleclumab in Resectable PDAC

Who this might be right for
Pancreatic Ductal Adenocarcinoma
University Health Network, Toronto 22
Testing effectiveness (Phase 2)UnknownNCT02978547
What this trial is testing

The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma

Who this might be right for
Resectable Pancreatic Ductal Adenocarcinoma
British Columbia Cancer Agency 20
Not applicableLooking for participantsNCT06287749
What this trial is testing

French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)

Who this might be right for
Pancreatic Cancer ResectablePancreatic Ductal AdenocarcinomaMinimal Residual Disease+2 more
University Hospital, Montpellier 37
Testing effectiveness (Phase 2)Looking for participantsNCT05851924
What this trial is testing

NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)

Who this might be right for
Pancreatic Ductal Adenocarcinoma
Memorial Sloan Kettering Cancer Center 60
Testing effectiveness (Phase 2)Study completedNCT03727880
What this trial is testing

Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma

Who this might be right for
Resectable Pancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Ductal Adenocarcinoma
Lei Zheng 28
Testing effectiveness (Phase 2)Active Not RecruitingNCT05642962
What this trial is testing

Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)

Who this might be right for
Metastatic Pancreatic Ductal AdenocarcinomaMetastatic Pancreatic CancerMetastatic Pancreatic Adenocarcinoma+10 more
Memorial Sloan Kettering Cancer Center 17
Testing effectiveness (Phase 2)Study completedNCT05262855
What this trial is testing

Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma

Who this might be right for
PDAC - Pancreatic Ductal AdenocarcinomaFAP
SOFIE 58
Testing effectiveness (Phase 2)Ended earlyNCT04176952
What this trial is testing

PRIMUS002: Looking at 2 Neo-adjuvant Treatment Regimens for Resectable and Borderline Resectable Pancreatic Cancer

Who this might be right for
Neoplasms Pancreatic
Judith Dixon-Hughes 31
Early research (Phase 1)Ended earlyNCT02782182
What this trial is testing

Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study

Who this might be right for
Pancreatic Ductal Adenocarcinoma (PDAC)
University of Chicago 1
Testing effectiveness (Phase 2)Looking for participantsNCT03977233
What this trial is testing

Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer

Who this might be right for
Pancreatic Ductal Adenocarcinoma (PDAC)Cancer of PancreasPancreatic Cancer, Adult+4 more
UNC Lineberger Comprehensive Cancer Center 45
Testing effectiveness (Phase 2)Study completedNCT03496662
What this trial is testing

BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

Who this might be right for
Pancreatic Ductal Adenocarcinoma
Washington University School of Medicine 40
Early research (Phase 1)Looking for participantsNCT06639724
What this trial is testing

Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer

Who this might be right for
Pancreatic Ductal Adenocarcinoma (PDAC)
University of California, San Diego 36
Early research (Phase 1)Looking for participantsNCT06673017
What this trial is testing

PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)

Who this might be right for
Pancreatic Ductal AdenocarcinomaBorderline Resectable Pancreatic AdenocarcinomaLocally Advanced Pancreatic Adenocarcinoma+1 more
PanTher Therapeutics 26
Not applicableLooking for participantsNCT07157605
What this trial is testing

Oncological Safety of Spleen Preservation in Left Pancreatectomy for Pancreatic Ductal Adenocarcinoma (SPLENDID)

Who this might be right for
Pancreatic Cancer ResectablePancreatectomy
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) 94
Load More Results